| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0213-005X(12)70069-1 |
| P8608 | Fatcat ID | release_ljj37gvtrvcbppdu3a33fx3gva |
| P698 | PubMed publication ID | 22541973 |
| P2093 | author name string | M Carmen Fariñas | |
| José Barberán | |||
| P2860 | cites work | Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells | Q24682375 |
| Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus | Q28272797 | ||
| Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin | Q28277284 | ||
| Skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus USA300 clone | Q33686212 | ||
| In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains | Q33979251 | ||
| Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms | Q34045376 | ||
| Complicated infections of skin and skin structures: when the infection is more than skin deep | Q34321629 | ||
| The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections | Q34330270 | ||
| Rapidly progressive soft tissue infections. | Q34437573 | ||
| The role of nasal carriage in Staphylococcus aureus infections | Q34470454 | ||
| Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus | Q34680589 | ||
| Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes | Q34718540 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects | Q34882125 | ||
| Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus | Q36903680 | ||
| Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007. | Q37190789 | ||
| The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas | Q37250567 | ||
| Skin and soft tissue infection: microbiology and epidemiology | Q37533547 | ||
| Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis | Q37637758 | ||
| Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections | Q37739469 | ||
| Complicated skin and soft tissue infection | Q37793714 | ||
| Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient--a review of the literature | Q37824612 | ||
| Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus | Q38898667 | ||
| Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers | Q39650862 | ||
| Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment | Q39758272 | ||
| Prospective, non-comparative study of daptomycin for the treatment of superficial and deep incisional surgical site infections | Q39779227 | ||
| In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin | Q40088863 | ||
| Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin | Q40275617 | ||
| Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth | Q41817273 | ||
| Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. | Q41862729 | ||
| Regulation of mprF by Antisense RNA Restores Daptomycin Susceptibility to Daptomycin-Resistant Isolates of Staphylococcus aureus | Q42053245 | ||
| Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm | Q42111239 | ||
| Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. | Q43041506 | ||
| Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections | Q43106836 | ||
| Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility | Q43433837 | ||
| Activity of daptomycin against staphylococci collected from bloodstream infections in Spanish medical centers | Q43615466 | ||
| Emergence of a single clone of community-associated methicillin-resistant Staphylococcus aureus in southern Madrid children | Q43728691 | ||
| In vitro bactericidal activity of daptomycin against staphylococci | Q43895572 | ||
| Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections. | Q44466641 | ||
| Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections | Q44958309 | ||
| Clinical and molecular epidemiology of community-acquired, healthcare-associated and nosocomial methicillin-resistant Staphylococus aureus in Spain | Q45021662 | ||
| A high-morbidity outbreak of methicillin-resistant Staphylococcus aureus among players on a college football team, facilitated by cosmetic body shaving and turf burns | Q45152098 | ||
| Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections | Q45230598 | ||
| Daptomycin for the treatment of surgical site infections. | Q45921783 | ||
| [Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci]. | Q46030066 | ||
| Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype | Q46079303 | ||
| Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin | Q46187290 | ||
| Community-acquired methicillin-resistant Staphylococcus aureus | Q46188100 | ||
| A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria | Q46459065 | ||
| Inappropriate therapy for methicillin-resistant Staphylococcus aureus: resource utilization and cost implications | Q46505822 | ||
| Staphylococcus spp. in Spain: present situation and evolution of antimicrobial resistance (1986-2006) | Q46596272 | ||
| Community-acquired methicillin-resistant Staphylococcus aureus infections: an emerging threat in Spain. | Q46812091 | ||
| Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
| Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin | Q46974823 | ||
| Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). | Q54453191 | ||
| Comparative randomised clinical trial against glycopeptides supports the use of daptomycin as first-line treatment of complicated skin and soft-tissue infections | Q58493989 | ||
| Cellulitis: evaluation of possible predisposing factors in hospitalized patients | Q78164533 | ||
| Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 | Q80595494 | ||
| P407 | language of work or name | Spanish | Q1321 |
| P304 | page(s) | 33-37 | |
| P577 | publication date | 2012-02-01 | |
| P1433 | published in | Infectious Diseases and Clinical Microbiology | Q15766978 |
| P1476 | title | Daptomycin in complicated skin and soft tissue infections | |
| P478 | volume | 30 Suppl 1 |
| Q33784232 | Prevalence and factors associated with wound colonization by Staphylococcus spp. and Staphylococcus aureus in hospitalized patients in inland northeastern Brazil: a cross-sectional study | cites work | P2860 |
Search more.